14 papers
Time restricted
14 publications — 6 trials, 5 syntheses.
Dak li din is-sit huwa mibni fuqu, suġġett b'suġġett: kemm artikli, kemm huma trials, u kemm huma reċenti. Ġenerat mill-ġbir, għalhekk ma jistax jaħrab mill-evidenza nnifisha.
14 papers
14 publications — 6 trials, 5 syntheses.
13 papers
13 publications — 3 trials, 7 syntheses.
12 papers
12 publications — 4 trials, 4 syntheses.
10 papers
10 publications — 2 trials, 6 syntheses.
10 papers
10 publications — 3 trials, 6 syntheses.
9 papers
9 publications — 3 trials, 5 syntheses.
9 papers
9 publications — 5 trials, 1 synthesis.
8 papers
8 publications — 3 trials, 3 syntheses.
7 papers
7 publications — 1 trial, 5 syntheses.
What the trials actually show about semaglutide, tirzepatide and the rest of the GLP-1 class.
Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.
Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.
Sleep, circadian rhythm and the wearables that claim to measure both.
Din il-paġna ġiet tradotta awtomatikament mill-Ingliż. Il-citazzjonijiet u n-numri mhumiex mibdula. Aqra l-original Ingliż jekk xi ħaġa taqra b'mod stramb. Aqra l-original Ingliż